Rheumatology

                   
pharmiweb.co.uk: PharmiWeb.com, From PharmiWeb Solutions pharmiweb.co.uk

New Study Shows ENBREL® (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms...

pharmiweb.co.uk
29-Oct-2008
        

receiving sulphasalazine, a disease modifying antirheumatic drug (DMARD) and significant differences were reported as early as 2 weeks. It is characterised by persistent lower back pain and progressive stiffness of the...

add comment
                   

Better Interaction And Education Between Rheumatoid Arthritis Patients And Care Providers Needed,...

medicalnewstoday.com
28-Oct-2008
        

UCB announced today findings from large-scale rheumatoid arthritis (RA) surveys collectively called the DESIGN study that showed patients rating themselves as having substantially less knowledge of RA therapies than their...

add comment

Nanocort® Demonstrates Safety And Good Response In Phase I/II Trial

bioresearchonline.com
28-Oct-2008
        

Galapagos NV (Euronext: GLPG) announces that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

add comment
                   

CORRECTING and REPLACING University of Kentucky Launches Clinical Outcomes-Based Educational...

yahoo.com
28-Oct-2008
        

Tuesday October 28, 4:01 pm ET Program to Address Physician Gaps in Managing Rheumatic Conditions and Improve Patient Care and Outcomes NEW YORK--(BUSINESS WIRE)--In third graph of release dated Oct. 27, 2008, the second...

add comment

Galapagos NV (BE) - Nanocort demonstrates safety and good response in Phase I/II trial

drugs.com
29-Oct-2008
        

Results to be presented today at the 2008 American College of Rheumatology Annual Scientific Meeting in San Francisco, USA MECHELEN, Belgium; 27 October 2008 - Galapagos NV (Euronext: GLPG) announces that Nanocort has...

add comment
                   

Nuvo Research Presents Positive Phase III Study Results for Pennsaid at Leading Rheumatology...

drugs.com
29-Oct-2008
        

MISSISSAUGA, ON, October 27, 2008 /PRNewswire-FirstCall/ - Nuvo Research Inc. , a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical...

add comment

Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of...

drugs.com
29-Oct-2008
        

LUND, Sweden, Oct. 28, 2008-Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the...

add comment
                   

Data Demonstrate Orencia (abatacept) Improves Health-Related Quality of Life, Pain and Sleep...

drugs.com
29-Oct-2008
        

SAN FRANCISCO--(BUSINESS WIRE)--Oct 28, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study...

add comment
                   

More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA(R) And Methotrexate...

medicalnewstoday.com
28-Oct-2008
        

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX)...

add comment
                   

Nuvo Research Presents Positive Phase III Study Results For Pennsaid At Leading Rheumatology...

medicalnewstoday.com
28-Oct-2008
        

Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies,...

add comment